Overview

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Status:
Recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
This research study is studying a drug as a possible treatment for BPDCN. The intervention involved in this study is: Venetoclax
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
AbbVie
Treatments:
Venetoclax